IL22 and metabolic dysfunction-associated steatotic liver disease: Using a rat NAFLD model, Zhu et al. [71] found that IL-22 participates in blueberry combined with probiotic therapy by activating the Janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) signaling pathway and inhibiting the apoptotic factor Bcl-2-associated X protein (Bax).